Omid Cameron Farokhzad
Born1969
Tehran, Iran
NationalityIranian, American
CitizenshipUnited States
Alma materUniversity of Massachusetts
Boston University
Massachusetts Institute of Technology
AwardsEllis Island Medal of Honor National Academy of Inventors
Scientific career
FieldsNanomedicine, Medical Nanotechnology
InstitutionsBrigham and Women's Hospital, Harvard Medical School, Seer Inc.

Omid Farokhzad (Persian: امید فرخزاد; born 1969) is an Iranian-American physician, scientist, and entrepreneur in the development of nanomedicines. Farokhzad is a Professor of Anesthesiology at Harvard Medical School.[1][2][3][4] Omid Farokhzad is the Chair, Chief Executive Officer and co-founder for Seer, a company focused on deep, unbiased proteomics analysis at scale.[5] The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations.[6]

He has also served as an associate editor for ACS Nano an international forum for the communication of comprehensive articles on nanoscience and nanotechnology research at the interfaces of chemistry, biology, materials science, physics, and engineering.[7] He is widely recognized as leader in the field of nanomedicine and drug delivery.[8][9][10][11]

In 2016, he was the recipient of the Ellis Island Medal of Honor.[12] He was also elected in the National Academy of Inventors in 2018.[13]

Career

Farokhzad completed his residency in Anesthesiology and fellowship in Pain Medicine at the Brigham and Women Hospital and Harvard Medical School. He completed a post-doctoral research training with Professor Robert Langer at MIT in the Harvard-MIT Program of Health Sciences and Technology. He joined Harvard Medical School in 2004 as a faculty member, after his clinical training, he served as Professor of Anesthesia.[14]

He has popularized the usage of specific targeting agents for the delivery of chemotherapy agents to cancerous cells found within a cancer patient. Beyond cancerous phenotype he has addressed atherosclerosis-related disease, He has demonstrated the usage of targeted biodegradable nano ‘drones’ that delivered a special type of drug that promotes healing. This remodeling of the plaque environment would be predicted in humans to block plaque rupture and thrombosis and prevent heart attacks and strokes.[15][16]

Farokhzad founded Seer, Inc. (Nasdaq: SEER) in 2017 to advance transformative proteomics platform that uses nanoparticles to analyze the protein compositions of a sample.[17][18][19][20]

Awards

References

  1. ↑ "Omid C. Farokhzad: Executive Profile & Biography - Bloomberg". www.bloomberg.com. Retrieved 2019-04-07.
  2. ↑ Wall Street Journal (2013-05-30), Welcome to the Era of Nanomedicine, retrieved 2019-03-25
  3. ↑ "Omid C. Farokhzad, MD - DF/HCC". www.dfhcc.harvard.edu. Retrieved 2019-03-24.
  4. ↑ IINE (2014-12-03), GDA 2014 Honoree: Dr. Omid Farokhzad, retrieved 2019-03-25
  5. ↑ "Management Team | Seer, Inc".
  6. ↑ "Top innovators in Massachusetts - The Boston Globe". BostonGlobe.com. Retrieved 2019-04-14.
  7. ↑ "Editorial Board". pubs.acs.org. Retrieved 2019-03-04.
  8. ↑ Venule endothelial cell genes and uses thereof, retrieved 2019-04-19
  9. ↑ High-throughput synthesis of nanoparticles, retrieved 2019-04-19
  10. ↑ Research, American Association for Cancer (2016-11-04). "Q&A: Omid Farokhzad on Nanomedicine in Cancer". Cancer Discovery. 6 (12): 1300. doi:10.1158/2159-8290.CD-ND2016-007. ISSN 2159-8274. PMID 27815294.
  11. ↑ Farokhzad, Omid C.; Langer, Robert (2009-01-27). "Impact of Nanotechnology on Drug Delivery". ACS Nano. 3 (1): 16–20. doi:10.1021/nn900002m. ISSN 1936-0851. PMID 19206243.
  12. ↑ "Eight Iranian Americans Awarded the 2016 Ellis Island Medal of Honor". PAAIA. 2016-03-21. Retrieved 2019-03-04.
  13. ↑ "Fellows List - National Academy of Inventors". academyofinventors.org. Retrieved 2019-04-14.
  14. ↑ "Omid C. Farokhzad, MD - DF/HCC". www.dfhcc.harvard.edu. Retrieved 2019-05-15.
  15. ↑ Tabas, Ira; Farokhzad, Omid; Perretti, Mauro; Kuriakose, George; Chiasson, Raymond; Ghorpade, Devram; Milton, Jaclyn; Spolitu, Stefano; Kamaly, Nazila (2015-02-18). "Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice". Science Translational Medicine. 7 (275): 275ra20. doi:10.1126/scitranslmed.aaa1065. ISSN 1946-6234. PMC 4397585. PMID 25695999.
  16. ↑ Kamaly, Nazila; Fredman, Gabrielle; Fojas, Jhalique Jane R.; Subramanian, Manikandan; Choi, Won II; Zepeda, Katherine; Vilos, Cristian; Yu, Mikyung; Gadde, Suresh (2016-05-24). "Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis". ACS Nano. 10 (5): 5280–5292. doi:10.1021/acsnano.6b01114. ISSN 1936-0851. PMC 5199136. PMID 27100066.
  17. ↑ "Seer | Proteomics Technology and Nanoparticles". 20 June 2022.
  18. ↑ "Seer raises another $55M and finally reveals proteomic tech — can it hold up?".
  19. ↑ "Omid Farokhzad, CEO of Seer, is a serial entrepreneur. His latest venture promises to disrupt the field of protein research - San Francisco Business Times". San Francisco Business Times.
  20. ↑ Blume, John E.; Manning, William C.; Troiano, Gregory; Hornburg, Daniel; Figa, Michael; Hesterberg, Lyndal; Platt, Theodore L.; Zhao, Xiaoyan; Cuaresma, Rea A.; Everley, Patrick A.; Ko, Marwin; Liou, Hope; Mahoney, Max; Ferdosi, Shadi; Elgierari, Eltaher M.; Stolarczyk, Craig; Tangeysh, Behzad; Xia, Hongwei; Benz, Ryan; Siddiqui, Asim; Carr, Steven A.; Ma, Philip; Langer, Robert; Farias, Vivek; Farokhzad, Omid C. (2020). "Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona". Nature Communications. 11 (1): 3662. Bibcode:2020NatCo..11.3662B. doi:10.1038/s41467-020-17033-7. PMC 7376165. PMID 32699280.
  21. ↑ "The Mustafa Prize Laureates 2023". mustafaprize.org. Retrieved 2024-01-07.
  22. ↑ iusnews (2024-01-07). "برگزیدگان جشنواره قلم داران معرفی شدند". خبرنامه دانشجویان ایران (in Persian). Retrieved 2024-01-07.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.